These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 27367558)

  • 1. Immune checkpoint blockade - a treatment for urological cancers?
    Elhage O; Galustian C; Dasgupta P
    BJU Int; 2016 Oct; 118(4):498-500. PubMed ID: 27367558
    [No Abstract]   [Full Text] [Related]  

  • 2. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
    Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
    Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune Checkpoint Inhibitors for Urologic Cancer: The Tip of the Iceberg?
    Powles T
    Eur Urol; 2015 Aug; 68(2):280-2. PubMed ID: 25800945
    [No Abstract]   [Full Text] [Related]  

  • 4. New checkpoint inhibitors ride the immunotherapy tsunami.
    Mullard A
    Nat Rev Drug Discov; 2013 Jul; 12(7):489-92. PubMed ID: 23812256
    [No Abstract]   [Full Text] [Related]  

  • 5. Checkpoint blockade immunotherapy for cancer comes of age.
    Brower V
    J Natl Cancer Inst; 2015 Mar; 107(3):. PubMed ID: 25745014
    [No Abstract]   [Full Text] [Related]  

  • 6. Immune Checkpoint Inhibitors.
    Haanen JB; Robert C
    Prog Tumor Res; 2015; 42():55-66. PubMed ID: 26382943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Checkpoint inhibitors in bladder and renal cancers: results and perspectives.
    Aoun F; Kourie HR; Sideris S; Roumeguère T; van Velthoven R; Gil T
    Immunotherapy; 2015; 7(12):1259-71. PubMed ID: 26595284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Era of Immune Checkpoint Therapy: From Cancer to Viral Infection-A Mini Comment on the 2018 Medicine Nobel Prize.
    Liu J; Pan W; Yang D
    Virol Sin; 2018 Dec; 33(6):467-471. PubMed ID: 30570713
    [No Abstract]   [Full Text] [Related]  

  • 9. Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy.
    Bang A; Wilhite TJ; Pike LRG; Cagney DN; Aizer AA; Taylor A; Spektor A; Krishnan M; Ott PA; Balboni TA; Hodi FS; Schoenfeld JD
    Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):344-351. PubMed ID: 28463153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. B7-H1/PD-1 blockade therapy in urological malignancies: current status and future prospects.
    Yu L; Wang Y; Shao S; Yang M; Niu H; Yu Q; Wang X
    Tumori; 2015; 101(5):549-54. PubMed ID: 26045125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse events associated with immune checkpoint inhibitor treatment for cancer.
    Esfahani K; Meti N; Miller WH; Hudson M
    CMAJ; 2019 Jan; 191(2):E40-E46. PubMed ID: 30642824
    [No Abstract]   [Full Text] [Related]  

  • 12. The State of Immune Checkpoint Inhibition in Urothelial Carcinoma: Current Evidence and Future Areas of Exploration.
    Campbell MT; Siefker-Radtke AO; Gao J
    Cancer J; 2016; 22(2):96-100. PubMed ID: 27111904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarkers for immunotherapy in urological cancers.
    Gust KM; Resch I; D'Andrea D
    Curr Opin Urol; 2018 Jan; 28(1):25-28. PubMed ID: 29120910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune checkpoint blockade in lymphoid malignancies.
    Thanarajasingam G; Thanarajasingam U; Ansell SM
    FEBS J; 2016 Jun; 283(12):2233-44. PubMed ID: 26807978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathogenesis, clinical manifestations and management of immune checkpoint inhibitors toxicity.
    Inno A; Metro G; Bironzo P; Grimaldi AM; Grego E; Di Nunno V; Picasso V; Massari F; Gori S
    Tumori; 2017 Sep; 103(5):405-421. PubMed ID: 28497847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune checkpoint blockade in hematologic malignancies.
    Armand P
    Blood; 2015 May; 125(22):3393-400. PubMed ID: 25833961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune checkpoints and rheumatic diseases: what can cancer immunotherapy teach us?
    van der Vlist M; Kuball J; Radstake TR; Meyaard L
    Nat Rev Rheumatol; 2016 Oct; 12(10):593-604. PubMed ID: 27539666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Checkpoint inhibitors: outstanding efficacy but at what cost?
    Klastersky JA
    Curr Opin Oncol; 2016 Jul; 28(4):253. PubMed ID: 27163724
    [No Abstract]   [Full Text] [Related]  

  • 19. Cancer immunotherapy using checkpoint blockade.
    Ribas A; Wolchok JD
    Science; 2018 Mar; 359(6382):1350-1355. PubMed ID: 29567705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics of Immune Checkpoint Inhibitors Trials Associated With Inclusion of Patients With HIV: A Systematic Review and Meta-analysis.
    Sorotsky H; Hogg D; Amir E; Araujo DV
    JAMA Netw Open; 2019 Nov; 2(11):e1914816. PubMed ID: 31702796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.